Varian Halcyon Treatment System Receives Taiwan FDA Approval

PALO ALTO, Calif., Jan. 8, 2018 - Varian (NYSE: VAR) today announced its Halcyon™ system has received Taiwan FDA approval, which allows the company to market this new cancer treatment system in Taiwan. This approval further expands the global availability of Halcyon and high-quality, cost-effective cancer treatments. As an advanced cancer treatment system with a human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow, accelerate installation...This story is related to the following:Clinical Medical Equipment
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news